Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival

Oncology

Volumn 55, Issue 4, 1998, Pages 363-369

  Kornmann, Marko ^a   Ishiwata, Toshiyuki ^a   Itakura, Jun ^a   Tangvoranuntakul, Pam ^a   Beger, Hans G ^b   Korc, Murray ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Cyclin D1; Pancreatic cancer; Prognostic parameter

Indexed keywords

CYCLIN D1; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PANCREAS CANCER; PANCREAS SURGERY; PRIORITY JOURNAL;

ADULT; AGED; BLOTTING, NORTHERN; CYCLIN D1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; REGRESSION ANALYSIS; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0031812131     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011879     Document Type: Article

References (22)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 1996;65: 5-27.
2. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 1989;49:4682-4689.
3. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Büchler M, Beger HG, Korc M: p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-160.
4. Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271:350-360.
5. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Büchler M, Beger HG: Overexpression of the epidermal growth factor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90:1352-1360.
6. Yamanaka Y, Friess H, Büchler M, Beger HG, Uchida E, Onda M, Kobrin MS, Korc M: Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993; 53:5289-5296.
7. Kobrin MS, Yamanaka Y, Friess H, Lopez ME, Korc M: Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res 1993;53:4741-4744.
8. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M: Insulin-like growth factor I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles. Cancer Res 1995;55:2007-2011.
9. Grana X, Reddy EP: Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-219.
10. Sherr CJ: G1 phase progression: Cyclin on cue. Cell 1994;79:551-555.
11. Motokura T, Arnold A: Cyclins and oncogenesis. Biochim Biophys Acta 1993;1155:63-78.
12. Hermanek P, Sobin LH: UICC, TNM Classification of Malignant Tumors. New York, Springer, 1987.
13. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TWJ, Home CHW: Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995;11:885-891.
14. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T: Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 1995;146:1161-1169.
15. Pines J: Protein kinases and cell cycle control. Semin Cell Biol 1994;5:399-408.
16. Draetta GF: Mammalian G1 cyclins. Curr Opin Cell Biol 1994;6:842-846.
17. Hall M, Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996; 68:67-108.
18. Zhou P, Jiang W, Zhang Y-J, Kahn SM, Schieren I, Santella RM, Weinstein B: Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 1995;11:571-580.
19. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, Beger HG: Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634-1637.
20. 1 events and regulation of cell proliferation. Science 1989;246:603-608.
21. Kornmann M, Arber N, Korc M: Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998;101:344-352.
22. Huang L, Lang D, Geradts J, Obara T, KleinSzanto AJ, Lynch HT, Ruggeri BA: Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. Mol Carcinog 1996;15:85-95.